parallel randomized trial
S003041
Type 2 diabetes (adults)S003041
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Linagliptin Linagliptin 5 mg | lifestyle: not reported | 18 | 15 | |
| A2 | Liraglutide 0.6 mg subcutaneous once daily Liraglutide 0.6 mg | lifestyle: not reported | 17 | 14 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Linagliptin A1 | Liraglutide 0.6 mg subcutaneous once daily A2 |
|---|---|---|---|
| age | mean (years) | 58.56 | 57.76 |
| age | sd (years) | 7.81 | 7.63 |
| bmi | mean (kg/m2) | 23.82 | 23.98 |
| bmi | sd (kg/m2) | 2.29 | 3.15 |
| diabetes duration | mean (years) | 4.00 | 3.59 |
| diabetes duration | sd (years) | 3.66 | 5.73 |
| female | n | 5 | 5 |
| hba1c | mean (percent) | 7.38 | 7.21 |
| hba1c | sd (percent) | 0.71 | 0.59 |
| other oad use | percent | 0 | 0 |
| sbp | mean (mmHg) | 130.44 | 128.24 |
| sbp | sd (mmHg) | 10.99 | 9.26 |
| waist | mean (cm) | 86.79 | 87.46 |
| waist | sd (cm) | 8.86 | 10.85 |
Analyses this trial contributes to
- Serious adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
- Discontinuation due to adverse eventsType 2 diabetes (adults); longest follow-up; descriptive only
- Discontinuation due to adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
- NauseaType 2 diabetes (adults); longest follow-up; network meta-analysis
- NauseaType 2 diabetes (adults); longest follow-up; network meta-analysis
- Discontinuation due to gastrointestinal adverse eventsType 2 diabetes (adults); longest follow-up; descriptive only
- Discontinuation due to gastrointestinal adverse eventsType 2 diabetes (adults); longest follow-up; network meta-analysis
Results
11 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (2 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; full analysis; R0020035:Results | ||||
| A2 | events | 0 / 17 | not stated; full analysis; R0020035:Results |
Discontinuation due to adverse events (2 lines; O26)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; randomized; R0020035:Supplement Figure S1 | ||||
| A2 | events | 0 / 17 | not stated; randomized; R0020035:Supplement Figure S1 |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; full analysis; R0020035:Results | ||||
| A2 | events | 1 / 17 | not stated; full analysis; R0020035:Results |
Vomiting (1 lines; O27B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; full analysis; R0020035:Results |
Diarrhea (1 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; full analysis; R0020035:Results |
Constipation (1 lines; O27D)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; full analysis; R0020035:Results |
Discontinuation due to gastrointestinal adverse events (2 lines; O27E)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 18 | not stated; randomized; R0020035:Supplement Figure S1 | ||||
| A2 | events | 0 / 17 | not stated; randomized; R0020035:Supplement Figure S1 |